Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Assets (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Assets for 6 consecutive years, with $56.7 million as the latest value for Q4 2025.

  • Quarterly Assets fell 43.04% to $56.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.7 million through Dec 2025, down 43.04% year-over-year, with the annual reading at $56.7 million for FY2025, 43.04% down from the prior year.
  • Assets hit $56.7 million in Q4 2025 for Bolt Biotherapeutics, down from $65.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $347.1 million in Q2 2021 to a low of $56.7 million in Q4 2025.
  • Historically, Assets has averaged $191.0 million across 5 years, with a median of $183.0 million in 2023.
  • Biggest five-year swings in Assets: skyrocketed 561.16% in 2021 and later plummeted 43.04% in 2025.
  • Year by year, Assets stood at $307.7 million in 2021, then decreased by 25.97% to $227.8 million in 2022, then dropped by 29.86% to $159.8 million in 2023, then tumbled by 37.65% to $99.6 million in 2024, then tumbled by 43.04% to $56.7 million in 2025.
  • Business Quant data shows Assets for BOLT at $56.7 million in Q4 2025, $65.1 million in Q3 2025, and $75.5 million in Q2 2025.